This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Dec 20;40(36):4279-4280.

doi: 10.1200/JCO.22.01470. Epub 2022 Aug 19.

Reply to R. Sun et al

Andrew J Armstrong¹, Brad Rosbrook¹, Shunsuke Yamada¹; ARCHES authors

Affiliations

Affiliation

¹ Andrew J. Armstrong, MD, ScM, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Brad Rosbrook, MS, Pfizer Inc, New York, NY; and Shunsuke Yamada, MEng, Astellas Pharma Inc, Northbrook, IL.

PMID: 35985006
DOI: 10.1200/JCO.22.01470

Comment

Reply to R. Sun et al

Andrew J Armstrong et al. J Clin Oncol. 2022.

. 2022 Dec 20;40(36):4279-4280.

doi: 10.1200/JCO.22.01470. Epub 2022 Aug 19.

Authors

Andrew J Armstrong¹, Brad Rosbrook¹, Shunsuke Yamada¹; ARCHES authors

Affiliation

¹ Andrew J. Armstrong, MD, ScM, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Brad Rosbrook, MS, Pfizer Inc, New York, NY; and Shunsuke Yamada, MEng, Astellas Pharma Inc, Northbrook, IL.

PMID: 35985006
DOI: 10.1200/JCO.22.01470

No abstract available

PubMed Disclaimer

Comment on

Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
Sun R, Wei LJ. Sun R, et al. J Clin Oncol. 2022 Dec 20;40(36):4278-4279. doi: 10.1200/JCO.22.01084. Epub 2022 Aug 19. J Clin Oncol. 2022. PMID: 35985008 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.